Recent Publications

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

June 06, 2019 | Earl H, Hiller L, Vallier A, Loi S, McAdam K, Hughes-Davies L, Harnett A, Ah-See M, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins H, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler–Araujo B, Provenzano E, Chhabra A, Abraham J, Caldas C, Hall P, McCabe C, Hulme C, Miles D, Wardley A, Cameron D

Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide…

Health Misinformation and the Power of Narrative Messaging in the Public Sphere

May 24, 2019 | Caulfield T, Marcon A, Murdoch B, Brown J, Tinker Perrault S, Jarry J, Snyder J, Anthony S, Brooks S, Master Z, Rachul C, Ogbogu U, Greenberg J, Zarzeczny A, Hyde-Lay R

Abstract: Numerous social, economic and academic pressures can have a negative impact on representations of biomedical research. We review several of the forces playing an increasingly…

Latest News

Next Event

IHE Database of Online Health Statistics